Table 3 Perceived safety of asthma medications during pregnancy in different trimesters (n = 174)
From: Management of asthma in pregnant women by general practitioners: A cross sectional survey
| Â | n (%) | |||||
|---|---|---|---|---|---|---|
| Â | First trimester | Second trimester | Third trimester | |||
Drug | Yes | No | Yes | No | Yes | No |
Cromones | ||||||
   Nedocromil | 88 (50.9%) | 41 (23.6%) | 102 (59.0%) | 22 (12.6%) | 100 (57.8%) | 23 (13.2%) |
   Sodium Cromoglycate | 112 (64.4%) | 29 (16.7%) | 125 (71.8%) | 15 (8.6%) | 123 (70.7%) | 17 (9.8%) |
Inhaled corticosteroids | ||||||
   Beclomethasone | 132 (75.9%) | 23 (13.2%) | 140 (80.5%) | 16 (9.2%) | 142 (81.6%) | 15 (8.6%) |
   Budesonide | 154 (88.5%) | 6 (3.4%) | 159 (91.4%) | 3 (1.7%) | 156 (89.7%) | 3 (1.7%) |
   Ciclesonide | 111 (63.8%) | 31 (17.8%) | 120 (69.0%) | 23 (13.2%) | 121 (69.5%) | 21 (12.1%) |
   Fluticasone | 133 (76.4%) | 26 (14.9%) | 144 (82.8%) | 14 (8.0%) | 147 (84.5%) | 11 (6.3%) |
Leukotriene receptor antagonists | ||||||
   Montelukast | 47 (27.0%) | 79 (45.4%) | 60 (34.5%) | 67 (38.5%) | 59 (33.9%) | 68 (39.1%) |
   Zafirlukast | 29 (16.7%) | 83 (47.7%) | 40 (23.0%) | 73 (42.0%) | 40 (23.0%) | 73 (42.0%) |
Long-acting beta 2 agonists | ||||||
   Eformoterol | 101 (58.0%) | 46 (26.4%) | 120 (69.0%) | 21 (12.1%) | 121 (69.5%) | 23 (13.2%) |
   Salmeterol | 105 (60.3%) | 44 (25.3%) | 124 (71.3%) | 20 (11.5%) | 125 (71.8%) | 22 (12.6%) |
Oral corticosteroids | ||||||
   Prednisolone | 141 (81.0%) | 20 (11.5%) | 151 (86.8%) | 8 (4.6%) | 149 (85.6%) | 12 (6.9%) |
Short-acting beta 2 agonists | ||||||
   Salbutamol | 167 (96.0%) | 0 (0.0%) | 164 (94.3%) | 0 (0.0%) | 164 (94.3%) | 1 (0.6%) |
   Terbutaline | 146 (83.9%) | 5 (2.9%) | 144 (82.8%) | 4 (2.3%) | 144 (82.8%) | 6 (3.4%) |